Publications by authors named "Roger Lyons"

Claim this Profile
T
Treatment patterns and overall survival among patients with myelodysplastic syndromes treated in the US community oncology setting: a real-world retrospective observational study.
Roger Lyons, Yanqing Xu, Cherrishe Brown-Bickerstaff, Ping Shi, Anders Svensson

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis.
Moshe Talpaz, Aaron T Gerds, Roger Lyons, Peter Langmuir, Deborah Hunter

Leuk Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.
Guillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, R Coleman Lindsley, Sarah M Larson, Roger Lyons

Ann Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics, blood counts, treatments, and clinical outcomes of 5871 patients with polycythemia vera treated in US community practices.
Roger M Lyons, Kathleen M Aguilar, Lavanya Sudharshan, Divea Venkatasetty, Juliet Ndukum

Curr Med Res Opin· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Michael Maris, Gilles Salles, Won Seog Kim, Tae Min Kim, Roger M Lyons

Target Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati, Roger M Lyons

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
Aaron T Gerds, Roger M Lyons, Philomena Colucci, Patricia Kalafut, Dilan Paranagama

Clin Lymphoma Myeloma Leuk· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study.
Abdulraheem Yacoub, Roger Lyons, Srdan Verstovsek, Ryan Shao, David Tin Chu

Clin Lymphoma Myeloma Leuk· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
Roger M Lyons, Mikhail Shtivelband, Edwin Kingsley, Mehdi Moezi, Donald Richards

Leuk Lymphoma· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method.
Adam Cuker, Jenny M Despotovic, Rachael F Grace, Caroline Kruse, Michele P Lambert, Roger M Lyons

Res Pract Thromb Haemost· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Sudhir Manda, Habte A Yimer, Stephen J Noga, Saulius Girnius, Christopher A Yasenchak, Roger Lyons

Clin Lymphoma Myeloma Leuk· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.
Fevzi F Yalniz, Jesus G Berdeja, Michael B Maris, Roger M Lyons, James A Reeves

Br J Haematol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Jatin Shah, Saad Usmani, Edward A Stadtmauer, Robert M Rifkin, James R Berenson, Roger M Lyons

Clin Lymphoma Myeloma Leuk· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
Xavier Leleu, Thomas G Martin, Hermann Einsele, Roger M Lyons, Brian G M Durie

Clin Lymphoma Myeloma Leuk· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Rami Komrokji, Arlene S Swern, David Grinblatt, Roger M Lyons, Magnus Tobiasson

Oncologist· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Pierre Fenaux, Petra Muus, Hagop Kantarjian, Roger M Lyons, Richard A Larson

Br J Haematol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia.
Douglas B Cines, Jeffrey Wasser, Francesco Rodeghiero, Beng H Chong, Michael Steurer, Roger Lyons

Haematologica· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G Berdeja, Yasmin Abaza, Elias Jabbour, Roger M Lyons

Cancer· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
James Berenson, Robert Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre, Roger Lyons

Am J Hematol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.
Roger M Lyons, Billie J Marek, Carole Paley, Jason Esposito, Katie McNamara

Leuk Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Vikas Gupta, John F DiPersio, Roger M Lyons

J Hematol Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
Ruben Mesa, Alessandro M Vannucchi, Abdulraheem Yacoub, Pierre Zachee, Mamta Garg, Roger Lyons

Br J Haematol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Gary E Raskob, Nick van Es, Annelise Segers, Pantep Angchaisuksiri, Doyeun Oh, Roger M Lyons

Lancet Haematol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
James R Berenson, Alan Cartmell, Alberto Bessudo, Roger M Lyons, Wael Harb

Blood· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Uwe Platzbecker, Raymond S M Wong, Amit Verma, Camille Abboud, Sergio Araujo, Roger Lyons

Lancet Haematol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis